Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.53 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29784832 | 0.94 | LMNA (0.55) | LMNASMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL2205405 | 0.94 | LMNA (0.55) | LMNASMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL8434561 | 0.88 | KMT2A (0.50) | LMNASMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL28664013 | 0.85 | MAPT (0.51) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL3266352 | 0.85 | LMNA (0.55) | LMNASMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL11237157 | 0.84 | POLB (0.60) | LMNASMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL2848376 | 0.84 | ALDH1A1 (0.63) | LMNASMN1; SMN2ALDH1A1KMT2AMEN1 | |
| SCHEMBL9396485 | 0.83 | MAPT (0.52) | LMNASMN1; SMN2ALDH1A1KMT2AKDM4E | |
| SCHEMBL28550137 | 0.83 | ALDH1A1 (0.53) | LMNASMN1; SMN2ALDH1A1KMT2AKDM4E | |
| SCHEMBL2929136 | 0.83 | NPSR1 (0.51) | LMNASMN1; SMN2ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | HOFFMANN-LA ROCHE INC. | 2018-10-18 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | HOFFMANN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-3252054-A1 | PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2017-12-06 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| EP-2593457-B1 | PYRAZOLO[1,5A]PYRIMIDINE AND THIENO[3,2B]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN LA ROCHE (CH) | 2017-08-23 | — | — | EP | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | HOFFMANN-LA ROCHE INC. | 2016-07-21 | — | — | US | disclosed |
| US-9255110-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | ROCHE PALO ALTO LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007375-A1 | PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| EP-1263503-B1 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | WYETH CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1549297-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | Wyeth Holdings Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040122048-A1 | Stabilized pharmaceutical composition containing basic excipients | WYETH HOLDINGS CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2004032909-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | WYETH HOLDINGS CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | disclosed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207936-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | LMNA 2020/4885SMN1; SMN2 1363/4885ALDH1A1 2519/4885 |
| US-10023589-B2 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | LMNA 2020/4885SMN1; SMN2 1363/4885ALDH1A1 2519/4885 |
| US-20040122048-A1 | Stabilized pharmaceutical composition containing basic excipients | F7, H1-10, F12 | LMNA 1455/4885SMN1; SMN2 3518/4885ALDH1A1 3199/4885 |
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | LMNA 2020/4885SMN1; SMN2 1363/4885ALDH1A1 2519/4885 |
| US-20180298026-A1 | Pyrazolo[1,5a]Pyrimidine Derivatives as IRAK4 Modulators | IRAK4, IRAK1, IRAK2 | LMNA 2020/4885SMN1; SMN2 1363/4885ALDH1A1 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.